Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL10-FTH-MSC
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intratumoral
01
Overview
CXCL10-FTH-MSC is an engineered cell therapy consisting of mesenchymal stem cells (MSCs) transduced with a recombinant lentivirus to overexpress the chemokine CXCL10, the anti-apoptotic transcription factor Nrf2, and a ferritin heavy chain (FTH) reporter gene. Developed for the treatment of glioblastoma (GBM), this therapeutic approach utilizes MSCs as a delivery vehicle to the tumor microenvironment. CXCL10 is intended to recruit and activate T lymphocytes, converting "cold" tumors into "hot" ones, while Nrf2 enhances the survival and oxidative stress tolerance of the MSCs within the hostile tumor environment. The inclusion of the FTH gene allows for non-invasive monitoring of the cells' distribution and persistence using MRI. Preclinical data indicates that peritumoral administration of these cells, particularly when combined with immune checkpoint blockade, can significantly inhibit tumor growth and improve survival by remodeling the immune landscape of the tumor.
- Other names
- CXCL10 and Nrf2-overexpressed MSCsCXCL-10 and Nrf2-overexpressed MSCsCXCL 10 and Nrf2-overexpressed MSCsCXCL10-Nrf2-FTH-MSCsCXCL-10-Nrf2-FTH-MSCsCXCL 10-Nrf2-FTH-MSCs
02
Targets
ARE-MSCs (Antioxidant Response Element (ARE) in engineered Mesenchymal Stem Cells)CCR3 (C-C chemokine receptor type 3)FTH1 (Ferritin heavy chain 1)
Beyond the preview
Go deeper on CXCL10-FTH-MSC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL10-FTH-MSC.